A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01682902
Recruitment Status : Completed
First Posted : September 11, 2012
Last Update Posted : January 9, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S